ImmuPharma plc (LON:IMM – Get Free Report)’s stock price fell 14.9% during trading on Thursday . The company traded as low as GBX 5.84 and last traded at GBX 6.30. 8,437,907 shares traded hands during trading, an increase of 6% from the average session volume of 7,955,658 shares. The stock had previously closed at GBX 7.40.
ImmuPharma Stock Performance
The company’s 50-day simple moving average is GBX 10.72 and its two-hundred day simple moving average is GBX 5.88. The firm has a market cap of £31.64 million, a PE ratio of -7.07 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- P/E Ratio Calculation: How to Assess Stocks
- Tesla Just Got Called a “Must Own” Stock—Here’s Why
- Best Aerospace Stocks Investing
- Why Gold Loves Trump as Much as Trump Loves Gold
- How to Invest in Small Cap Stocks
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
